Inhibition of Soluble Epoxide Hydrolase Prevents Docetaxel-Induced Painful Peripheral Neuropathy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26125630 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Karen M Wagner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA 95616, USA. Hauptthemen laut MEDLINE: Docetaxel, Epoxide Hydrolases, Peripheral Nervous System Diseases, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIEHS NIH HHS, National Institute of Environmental Health Sciences, NIEHS Superfund Research Program.
Abstract (Originalsprache)
Chemotherapy-induced peripheral neuropathy (CIPN) is a painful condition recalcitrant to current available therapies. CIPN pain can be severe and dose-limiting or dose-reducing for life-extending chemotherapeutics and, to date, there is no treatment to alter the progression of CIPN. For these experiments we used docetaxel, a first-line therapy for metastatic prostate cancer in humans and investigated the soluble epoxide hydrolase inhibitor EC5026 for its analgesic efficacy against this CIPN pain. Male SD rats (n = 10/group) were pretreated with 1 mg/kg EC5026 in formulated drinking water or vehicle for one week prior to docetaxel injections. The rats continued the formulated drinking water during three once-a-week docetaxel 10 mg/kg i.p. injections and were maintained on treatment until the end of week 5 when all groups were transitioned to normal drinking water. Nociceptive testing occurred throughout the entire experiment including after transitioning to normal drinking water. EC5026 increased mechanical withdrawal thresholds and latencies on the cold plate compared to docetaxel-treated controls. There were no motor effects of the compound, and the formulated drinking water provided favorable exposure. These results demonstrated that EC5026 administered prophylactically was both analgesic and able to limit the severity of mechanical and cold sensitivities in the docetaxel CIPN rat model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Entomology and Nematology and UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA 95616, USA.
ORCID-Profile: Karen M Wagner, Jun Yang, Christophe Morisseau, Bruce D Hammock
Förderung
- NCI NIH HHS
- NIEHS NIH HHS
- National Institute of Environmental Health Sciences, NIEHS Superfund Research Program
- National Institute of Environmental Health Sciences (NIEHS)
- NIEHS Superfund Research Program
Zitieren
APA
Wagner, K. M., Yang, J., Morisseau, C., & Hammock, B. D. (2025). Inhibition of Soluble Epoxide Hydrolase Prevents Docetaxel-Induced Painful Peripheral Neuropathy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125630
Vancouver
Wagner KM, Yang J, Morisseau C, Hammock BD. Inhibition of Soluble Epoxide Hydrolase Prevents Docetaxel-Induced Painful Peripheral Neuropathy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125630
BibTeX
@article{Wagner2025,
author = {Wagner, Karen M and Yang, Jun and Morisseau, Christophe and Hammock, Bruce D},
title = {Inhibition of Soluble Epoxide Hydrolase Prevents Docetaxel-Induced Painful Peripheral Neuropathy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26125630}
}
EUVIMED